HEALTHCARE INNOVATION FORUM 2018

Program
February 23rd, 2018
Lithuanian Academy of Sciences

09:30 Registration, welcome coffee

10:00 Welcome speeches
Prof. Vytautas Basys
Secretary General at Lithuanian Academy of Sciences
Ruta Pumputiene
Attorney-at-law, Head of Local American Working Group

10:10 Keynote speaker
Is Big Pharma a player in the local innovation ecosystem?
Anthony Gemmell
Senior Director of EMEA Network New Ventures and Transactions at Johnson & Johnson Innovation

10:40 Keynote speaker
Innovation vs. Price. How do we build a sustainable ecosystem in Healthcare? Trends and developments from Global, European and Nordic perspectives
Torsten Lindström
Partner, Senior Vice President and European Healthcare Director at Rud Pedersen Group

11:10 Panel discussion
Horizon scanning: why & how to launch it in Lithuania?
Dr. Alvydas Česas
Chief of Oncology & Chemotherapy Clinic at Klaipeda University Hospital, President of the Lithuanian Society for Medical Oncology
Per Troein
Vice President of Strategic Partners at IQVIA
Dr. Rafael Popper
Principal scientist at VTT Technical Research Centre of Finland Ltd

12:10 Networking break, refreshment

13:00 Panel discussion
Challenges to healthcare innovations within the Baltics
Kristina Garuolienė
Vice Minister of Health of the Republic of Lithuania
Paulius Gradeckas
Adviser to the Prime Minister for Health, Youth and NGO
Liudas Krisiukėnas
Market Access and Governmental Affairs Manager at AbbVie
Rūta J. Laukien
Director at C.W. Downer

14:00 Keynote speaker
Future of Pharma, Biotech and Healthcare in OECD countries and Lithuania
Richard P. Kivel
Managing Director at Graybella Capital
Panel discussion
*
**Real measures countries need to take to promote life sciences entrepreneurship**

Daina Kleponė  
Executive Director at Enterprise Lithuania

Agnė Vaitkevičienė  
Chief Executive Officer at UAB Froceth

Dr. Monika Kavaliauské  
Chief Executive Officer at CasZyme

Gabrielius Jakutis  
Team leader at “Vilnius-Lithuania iGEM”

Aurimas Pečkauskas  
Board Member at Junior Doctors Association

15:30 Goodbye & aperitifs

**SPEAKERS**

**Mr. Anthony Gemmel**  
Senior Director, EMEA Network New Ventures and Transactions at Johnson & Johnson Innovation

Mr. Anthony Gemmel is the Senior Director for the EMEA Innovation Leads Network and for Transactions at Johnson & Johnson Innovation. He is responsible for a team of New Venture Leads in Europe identifying, developing and executing transactions with a selection of the Innovation Centre’s diverse ecosystem of partners, including biotech companies, venture capital, non-profit organizations, governments and academic institutions.

Previously, Mr. Gemmel worked within several business development roles within the Johnson & Johnson Pharmaceutical Group Business Development including New Business Development, Mergers & Acquisitions and New Ventures, and has completed a wide variety of business development, licensing, acquisition and divestment assignments.

Prior to joining the Johnson & Johnson family of companies, Anthony had management roles in the UK and EMEA in New Product Development and Business Unit Management with Lilly, Servier and Bristol Myers Squibb spanning multiple disease areas.

He received his degree in Biological Sciences from Durham University and his MBA from the London Business School.

**Mr. Lindström**  
Partner, Senior Vice President and European Healthcare Director for the Rud Pedersen Group

Mr. Lindström’s expertise is in strategic communication within the political business environment, creating value for all stakeholders at local, national, Nordic and European levels.

Torsten chairs the Rud Pedersen Healthcare team in Brussels and Nordic countries. His knowledge of the many and varied areas of healthcare and welfare systems in the Nordic countries and the EU is based on experience from several senior roles as manager, adviser and decision maker in both the public and private sectors.

He has previously been a member of the Swedish Parliament, a policy advisor in the Prime Minister’s office, a member of several hospital boards and an elected politician at both municipality and regional level. Torsten has an Executive MBA degree as well as degrees in History and Education. He has also taken courses in Management, Finance, Strategy and Healthcare.
Mr. Alvydas Ėsas is a certified physician and medical oncologist with over 20 years of experience in the field of oncology. He is currently the chief of Oncology and Chemotherapy Clinic at Klaipeda University Hospital, as well as the President of Lithuanian Society for Medical Oncology.

His fields of professional interest are colorectal cancer, breast cancer, uro-genital tract cancers, melanoma. Mr. Ėsas has authored and co-authored over 20 scientific publications.

Mr. Ėsas is also a full member of European society of medical oncology (ESMO), member of the Central European Cooperative Oncology Group (CECOG), Chairman of the National Cancer Prophylaxis and Control Program and the Monitoring Committee for the Organization of Oncological Assistance and a former Lithuanian National Representative in ESMO NR committee.

Mr. Troein has been with QI for 19 years and is responsible for the relationship with suppliers and associations. He has deep insight around generics and biosimilars and how they are handled in different markets. One of QI’s priorities is to have the best understanding of those dynamics to secure the most appropriate data, to be the best partner with the different data partners, and to be able to support the industry and also when appropriate governments. He is a well know speaker in the field of distribution trends and pricing and is very active in consulting projects in the area.

Prior to joining IMS, Per worked 13 years for Pharmacia in US and Europe. His last 6 years were spent in strategic development as a VP including several major mergers and acquisitions.

He holds an MSc in engineering from Lund’s Institute of Technology and an MBA from INSEAD.

Prof. Dr. Rafael Popper is Principal Scientist in Business, Innovation and Foresight at VTT Technical Research Centre of Finland Ltd, Professor of Foresight and Innovation Management at the National Research University Higher School of Economics (HSE) in Russia and Honorary Research Fellow at the Manchester Institute of Innovation Research (MIOIR) of the University of Manchester in the UK. He is also Director of Executive Education in Foresight and Innovation Futures at the Manchester Business School (MBS); Innovation Director and CEO of Futures Diamond Ltd in the UK and the Czech Republic.

His main areas of work include: ‘foresight’ as an instrument of innovation policy, the development of foresight and horizon scanning methodology, the design of forward-looking activities and their evaluation with a focus on technological and social innovation policies, and the assessment and management of sustainable innovations of different types, including: product, service, social, governance, organisational, marketing and system innovations.

Mrs. Kristina Garuolienė is a vice minister of Health of the Republic of Lithuania. Mrs. Garuolienė holds a medical doctor's degree from Vilnius University and is a professional pediatrician. She also holds a masters degree in public administration and a doctoral degree in biomedicine.

Prior to becoming vice minister at the Ministry of Health, she worked at the National Health Insurance Fund under the Ministry of Health – first as a chief officer at the department of medicine and expertise, then as a head of medicine reimbursement department. She has also been working as a lecturer at the Vilnius University Faculty of Medicine.
Mr. Gradeckas graduated from Kaunas University of Medicine (The present-day Lithuanian University of Health Sciences).
He obtained diploma in Intervention Epidemiology from European Centre for Disease Prevention and Control in 2013. From 2008 to 2011 he worked in the field of Public Health. He held a position of Medical Epidemiologist in Lithuanian and Hungarian centers for communicable diseases from 2011 to 2013.
He graduated from the program Create for Lithuania in 2014 and has been working in private sector until 2016 when he joined a team of incumbent Prime Minister of Republic of Lithuania.

Mr. Liudas Krisiukėnas is currently a Market Access and Governmental Affairs Manager at Abbvie. Before joining Abbvie he worked in different positions at Pfizer, Novarties and Eli Lilly & Company.
Mr. Krisiukėnas holds a MD degree in Medicine at Kaunas Medical University also studied Business management and administration and business law at Vytautas Magnus University.

Mrs. Rūta Jurevičiūtė Laukien has more than 12 years of investment-banking experience, including a strong background in M&A, debt capital markets and equity capital raises. She spent seven years as a Vice President at Bear Stearns, where she was part of the M&A, healthcare and financial sponsors groups and had primary coverage responsibility for 13 private equity and hedge funds. Currently Mrs. Laukien is a Director at C.W. Downer, an international middle-market investment bank, where she focuses on the healthcare industry, including biotechnology and life sciences and cross-border transactions.
Mrs. Laukien holds BA degrees in Economics and Psychology from the University of North Florida, an MBA from the Fuqua School of Business as well as a JD and Masters in International Law from Duke University Law School. She is admitted to practice law in New York State.

Mr. Kivel serves as Managing Director of GrayBella Capital LLC., a VC/PE investment fund focused on biotech, healthcare and technology companies in Europe.
Richard has served as a CEO, Chairman and Board Director in both private and public companies in Europe, Russia, Singapore and the US. Previously, he was a Senior Manager at Bridgewater Associates, the world's largest hedge fund, with $160 billion in global assets.
Richard is a guest lecturer on Global Entrepreneurship, Business Models and Venture Investing at MIT, Moscow School of Management Skolkovo and other universities in Europe and Singapore. He has many years of experience mentoring entrepreneurs in his role as Global Chairman of the MIT Enterprise Forum and Judge for the MIT $100K Entrepreneurship Competition. Richard also serves as a Trustee of the Bankinter Innovation Foundation, a global technology Think-Tank located in Spain and Portugal.
Richard Kivel
kivel@mit.edu
Twitter @kivel1

Mrs. Daina Kleponė is a managing director at Enterprise Lithuania, which is a trade promotion agency, established by the Ministry of Economy. Mrs. Kleponė has gained a comprehensive experience as a senior executive in leading multinational organisations and local projects across a wide range of different industries and markets.
Before taking a lead of Enterprise Lithuania, she was known as general management professional with history of significant profit, volume, market position achievements and proven track record from successful turnarounds, transitions and brand developments, driven with focus on planning, implementation and achievement of budgets for sales, income and costs.
After university studies in chemistry she followed with an MBA for international executives at the Baltic Management Institute. Daina was leading big local enterprises as “Šatrija”, “Baltika Lietuva”, “Audimas”, was in management board of biggest insurance company “Lietuvos Draudimas”, several years has been consulting foreign capital companies in Austria, Switzerland and India.
Mrs. Vaitkevičienė’s work in the field of cell therapy began at Vilnius University, where she earned a degree in Molecular Biology in 2005. During her studies, she took part in an internship at the university’s Institute of Immunology, allowing her to extend the knowledge on the theory and practises involved in the use of stem cells. Agne continued her studies in Spain, at the University of Barcelona, where she specialized in organ, tissue and cell transplantation, also participating in an internship at the Blood and Tissue Bank of Catalonia (BST).

Agne has been able to further develop the knowledge she acquired during her studies through the work at the National Public Health Surveillance Laboratory and at the first cord blood stem cell bank in Lithuania. Through the involvement in various courses and training programs, Agne has also received instruction in fundamental Good clinical practices (GCP), and has developed the skills in the areas of Good Manufacturing Practices (GMP), GMP laboratory maintenance, systems, cell therapy, regenerative medicine and methods for tissue and blood banking. Since end of 2014, together with partners, Agne established first and at this point the only Advanced therapy medicinal product manufacturing facility in the Baltic states and acts as a CEO of the company. Froceth is focused on developing cellular therapies and tissue engineered products for personalized treatment of various diseases such as cancer or multiple sclerosis.

Dr. Monika Kavaliauskė is CEO at CasZyme, a startup company founded in 2017, based in Vilnius, Lithuania. CasZyme aims to develop new discoveries, innovative applications and top-quality research in the field of CRISPR based Molecular Tools. Company seeks to create outstanding value for researchers and companies practicing gene-editing worldwide.

Dr. Monika Kavaliauskė previously established Innovations Office at Vilnius University, Lithuania and was managing it for 5 years. Dr. Monika Kavaliauskė also holds PhD in Social Sciences, and is experienced in biotech and pharma industries, high tech business development, technology transfer and marketing.

Mr. Jakutis is a last-year medical student at the Vilnius University, as well as Vilnius-Lithuania iGEM 2017 team leader and Science Development Coordinator at the Society of Innovative Medicine.

Together with his associates Gabrielius aims to promote an open, interdisciplinary, innovations-driven, and independent setting for students’ applied research in Lithuania. Gabrielius has given 10 poster or oral presentations in international medical congresses based on his clinical research at the Faculty of Medicine, and in a year 2017 together with a team of the brightest students of the Vilnius University Life Sciences Center, won a Grand Prize award at the international synthetic biology competition “iGEM”.

Mr. Peckauskas is an anaesthesiologist and a board member at Young Doctors Association of Lithuania.

Aurimas graduated from Lithuanian University of Health Sciences in 2016 and acquired an MD in Anesthesiology and Intensive care. He worked as an intensive care physician in the United Kingdom between 2014 and 2017. He has also received training in the Netherlands and Finland.

At the moment Mr. Peckauskas works as an anaesthesiologist and intensive care physician at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics. He also works as a lecturer for undergraduates and postgraduates at the Lithuanian University of Health Sciences.

Aurimas is also actively involved in non-governmental activities – he is one of the founders of Lithuanian Junior Doctors Association (JGA) and has been an executive board member since 2015. As of 2015 Aurimas also represents JGA at the European Junior Doctors Association (EJD) and acts as an executive board member.